BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23944368)

  • 1. CD95 signaling in cancer treatment.
    De la Rosa AJ; Gomez MA; Morales S; Padillo FJ; Muntane J
    Curr Pharm Des; 2014; 20(17):2809-18. PubMed ID: 23944368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD95 promotes tumour growth.
    Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME
    Nature; 2010 May; 465(7297):492-6. PubMed ID: 20505730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining CD95 as a tumor suppressor gene.
    Müschen M; Warskulat U; Beckmann MW
    J Mol Med (Berl); 2000; 78(6):312-25. PubMed ID: 11001528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.
    Risso V; Lafont E; Le Gallo M
    Cell Death Dis; 2022 Mar; 13(3):248. PubMed ID: 35301281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DICE: A novel tumor surveillance mechanism-a new therapy for cancer?
    Peter ME
    Cell Cycle; 2014; 13(9):1373-8. PubMed ID: 24690893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
    Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
    Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
    Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
    J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD95 ligand: lethal weapon against malignant glioma?
    Weller M; Kleihues P; Dichgans J; Ohgaki H
    Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of CD95 and CD95 ligand in cancer.
    Peter ME; Hadji A; Murmann AE; Brockway S; Putzbach W; Pattanayak A; Ceppi P
    Cell Death Differ; 2015 Apr; 22(4):549-59. PubMed ID: 25656654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD95 signaling in colorectal cancer.
    Hoogwater FJ; Steller EJ; Westendorp BF; Borel Rinkes IH; Kranenburg O
    Biochim Biophys Acta; 2012 Aug; 1826(1):189-98. PubMed ID: 22498253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
    Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
    Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
    Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
    Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
    Quijano-Rubio C; Silginer M; Weller M
    J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
    Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
    J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
    Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
    Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic drugs and the CD95 pathway.
    Friesen C; Fulda S; Debatin KM
    Leukemia; 1999 Nov; 13(11):1854-8. PubMed ID: 10557062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.
    Haymour L; Jean M; Smulski C; Legembre P
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189004. PubMed ID: 37865305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.
    Li-Weber M; Krammer PH
    Semin Immunol; 2003 Jun; 15(3):145-57. PubMed ID: 14563113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand.
    Ng CS; Lo ST; Chan JK
    Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD95 Stimulation with CD95L and DISC Analysis.
    Le Gallo M; Legembre P
    Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.